CRANBURY, N.J.–Rocket Pharmaceuticals reported a narrower third-quarter loss as the biotechnology company advanced several gene therapy programs for inherited heart diseases and prepared to begin commercial treatment with its recently approved therapy for a rare pediatric immune disorder.
The company reported a net loss of $49.2 million, or $0.43 per share, for the quarter ended September 30, 2026, compared with $50.3 million, or $0.45 per share, during the same period last year.
Rocket ended the quarter with approximately $279.4 million in cash, cash equivalents and investments, including $35 million received through a new financing agreement with Hercules Capital.
The company expects its available resources to support planned operations into the third quarter of 2028, with the possibility of extending that timeline into 2029 through additional borrowing, subject to financing conditions and spending requirements.
Rocket’s lead cardiovascular gene therapy candidate, RP-A501, is being evaluated in a pivotal Phase 2 clinical trial for Danon disease, a rare inherited disorder that causes progressive heart muscle damage and can lead to heart failure.
Following discussions with the U.S. Food and Drug Administration, Rocket has established an updated clinical development pathway for the treatment, including a modified dosing strategy and a 12-patient pivotal study population.
The company expects to complete patient dosing by mid-2027 and report topline trial results in mid-2028.
“With FDA alignment on the pivotal RP-A501 trial in Danon disease, our priority is to complete dosing by mid-2027,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharmaceuticals. “We are also advancing our broader cardiovascular portfolio, with dosing initiated in the Phase 1 trial of RP-A701 for BAG3-DCM and continued FDA engagement on a potential pivotal study of RP-A601 in PKP2-ACM. Commercial readiness for KRESLADI and activation of our first Qualified Treatment Centers bring us closer to treating eligible children. Our financial resources and the additional flexibility provided by the Hercules facility support these priorities as we work toward our next clinical and commercial milestones.”
Under the revised Phase 2 protocol, the first three patients treated with the modified regimen will count toward the trial’s 12-patient pivotal efficacy population.
To meet the study’s primary efficacy requirements, at least seven patients must demonstrate both sufficient expression of the LAMP2 protein in heart tissue and a reduction of at least 10% in left ventricular mass index after 12 months.
The endpoints are intended to support a potential accelerated approval pathway if the treatment demonstrates sufficient clinical benefit.
Rocket also reported encouraging initial safety observations among the first three patients treated under the revised protocol, along with updated longer-term findings from its earlier Phase 1 study.
The company estimates that approximately 10,000 to 11,000 people in the United States are living with Danon disease, including roughly 4,000 males. Rocket has identified more than 900 patients with the condition, although not all individuals would necessarily qualify for treatment.
Beyond RP-A501, Rocket is advancing two additional gene therapy programs targeting inherited cardiovascular conditions.
The company has initiated dosing in a Phase 1 clinical trial of RP-A701, an investigational treatment for BAG3-associated dilated cardiomyopathy, a genetic disorder that weakens the heart muscle and affects its ability to pump blood.
The multicenter trial is evaluating the treatment’s safety, biological activity and preliminary effectiveness in adults with the condition.
In October, the European Commission granted orphan designation to RP-A701, recognizing its development for a rare disease.
Rocket is also continuing its Phase 1 study of RP-A601, a gene therapy candidate targeting PKP2-associated arrhythmogenic cardiomyopathy, an inherited condition associated with abnormal heart rhythms and progressive heart damage.
Earlier clinical findings demonstrated increased PKP2 protein expression and improvements in certain biological measures related to heart function.
The company is continuing discussions with the FDA regarding a potential pivotal clinical trial while enrolling additional patients to evaluate the treatment across varying levels of disease severity.
Rocket also reached a commercial milestone with KRESLADI (marnetegragene autotemcel), its gene therapy for severe leukocyte adhesion deficiency-I, an ultra-rare and potentially fatal inherited immune disorder affecting children.
The company achieved commercial readiness for KRESLADI on October 1, 2026, with two Qualified Treatment Centers activated and prepared to begin enrolling eligible patients for treatment.
KRESLADI is designed to address the underlying genetic cause of the disease by introducing a functional copy of the ITGB2 gene into a patient’s own blood-forming stem cells.
The therapy is administered as a single intravenous infusion following conditioning treatment. It is intended to restore the function of immune cells responsible for fighting infections.
Severe leukocyte adhesion deficiency-I can cause repeated, life-threatening bacterial and fungal infections beginning in infancy.
The treatment received accelerated approval based on evidence of increased expression of proteins involved in immune cell function. Continued approval may depend on additional clinical evidence confirming its benefits.
KRESLADI carries significant safety risks, including serious infections, liver complications, potential failure of blood cell recovery and a long-term risk of blood cancers associated with the gene therapy process.
On the financial side, Rocket reported research and development expenses of $31.2 million for the third quarter, down from $34.1 million a year earlier.
The decrease primarily reflected lower personnel expenses, reduced manufacturing and development costs, and lower depreciation expenses, partially offset by increased laboratory, professional services and clinical trial spending.
General and administrative expenses increased to $19.8 million from $18.4 million, reflecting additional spending associated with commercial preparations and post-marketing commitments.
To strengthen its financial position, Rocket entered into a credit facility agreement with Hercules Capital in October that provides access to as much as $150 million.
The company received an initial $35 million and may access another $35 million during specified periods, subject to the agreement’s conditions.
An additional $30 million could become available following achievement of a specified Danon disease clinical milestone, while another $50 million would require approval from Hercules’ investment committee.
Rocket plans to use the financing to support its cardiovascular gene therapy pipeline, particularly the pivotal RP-A501 study and the continued development of its other investigational treatments.
The company’s upcoming milestones include completing dosing in the Danon disease trial, advancing its additional cardiac gene therapy programs and beginning commercial treatment of eligible patients with KRESLADI.


